| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1093/JAC/46.2.171 |
| P8608 | Fatcat ID | release_zrcamk4nzbev5k66wbqajtel2a |
| P3181 | OpenCitations bibliographic resource ID | 1278166 |
| P698 | PubMed publication ID | 10933638 |
| P50 | author | Henk-Jan Guchelaar | Q63658803 |
| P2093 | author name string | J Dankert | |
| A Vermes | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| clinical indication | Q110971784 | ||
| toxicity | Q274160 | ||
| pharmacokinetics | Q323936 | ||
| 5-fluorocytosine | Q238490 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 171-179 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions | |
| P478 | volume | 46 |
| Q33341541 | 5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study |
| Q92011714 | A Decade of Antifungal Leads from Natural Products: 2010-2019 |
| Q28554086 | A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer |
| Q59113329 | A Novel Approach of Targeted Immunotherapy against Adenocarcinoma Cells with Nanoparticles Modified by CD16 and MUC1 Aptamers |
| Q28548451 | A Phytase-Based Reporter System for Identification of Functional Secretion Signals in Bifidobacteria |
| Q47739279 | A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models |
| Q33985947 | A case of chromoblastomycosis with an unusual clinical manifestation caused by Phialophora verrucosa on an unexposed area: treatment with a combination of amphotericin B and 5-flucytosine |
| Q35666161 | A flucytosine-responsive Mbp1/Swi4-like protein, Mbs1, plays pleiotropic roles in antifungal drug resistance, stress response, and virulence of Cryptococcus neoformans |
| Q64234151 | A promising therapeutic strategy for metastatic gestational trophoblastic disease: Engineered anticancer gene-expressing stem cells to selectively target choriocarcinoma |
| Q40060948 | AFM combined to ATR-FTIR reveals Candida cell wall changes under caspofungin treatment |
| Q35053803 | Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey |
| Q64107158 | Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in |
| Q28831500 | Age and Gender Affect the Composition of Fungal Population of the Human Gastrointestinal Tract |
| Q27655618 | Alteration of enzyme specificity by computational loop remodeling and design |
| Q89683135 | An Overview on Conventional and Non-Conventional Therapeutic Approaches for the Treatment of Candidiasis and Underlying Resistance Mechanisms in Clinical Strains |
| Q92796887 | An in situ high-throughput screen identifies inhibitors of intracellular Burkholderia pseudomallei with therapeutic efficacy |
| Q92350952 | Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts |
| Q90363397 | Antifungal Drugs |
| Q39273596 | Antifungal activity of dual combination of hydroxychavicol with commercialized agents against oral Candida species |
| Q38858839 | Antifungal agents and liver toxicity: a complex interaction |
| Q37381931 | Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development |
| Q35072285 | Antifungal agents of use in animal health--chemical, biochemical and pharmacological aspects |
| Q35688450 | Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy |
| Q30433553 | Antifungal application of nonantifungal drugs |
| Q36201569 | Antifungal combination therapy: clinical potential |
| Q35575367 | Antifungal properties of peptidomimetics with an arginine-[β-(2,5,7-tri-tert-butylindol-3-yl)alanine]-arginine motif against Saccharomyces cerevisiae and Zygosaccharomyces bailii. |
| Q39751373 | Antifungal resistance and new strategies to control fungal infections |
| Q53289209 | Antifungal therapy: drug-drug interactions at your fingertips. |
| Q38111859 | Aspartic proteinases of Candida spp.: role in pathogenicity and antifungal resistance. |
| Q42776126 | Aspergillus spondylodiscitis in solid organ transplant recipients |
| Q37700360 | Augmenting podocyte injury promotes advanced diabetic kidney disease in Akita mice. |
| Q92002034 | Beyond tissue concentrations: antifungal penetration at the site of infection |
| Q36095320 | Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens |
| Q47342687 | CNS-manifestation of aspergillosis in an extremely low-birth-weight infant |
| Q90297410 | Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents |
| Q33775256 | Candida infections and their prevention |
| Q26863344 | Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents |
| Q51175452 | Candida urinary tract infections--treatment. |
| Q40064579 | Candidiasis and the impact of flow cytometry on antifungal drug discovery. |
| Q33364370 | Caspofungin: a potential cause of reversible severe thrombocytopenia |
| Q35678997 | Changing strategies for the management of invasive fungal infections |
| Q42141903 | Chemosensitization as a means to augment commercial antifungal agents |
| Q34505582 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
| Q34546811 | Clinical hepatotoxicity associated with antifungal agents |
| Q33676182 | Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine |
| Q38314467 | Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients |
| Q35129039 | Clinical pharmacology of antifungal compounds |
| Q36944929 | Clonal population of flucytosine-resistant Candida tropicalis from blood cultures, Paris, France |
| Q36369805 | Combination Antifungal Therapy: A Review of Current Data |
| Q44505735 | Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma |
| Q84629983 | Comparative in vitro activities of fluconazole, voriconazole, and MXP-4509 against Romanian blood yeast isolates |
| Q38284468 | Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. |
| Q77752654 | Cost-benefit analysis of the detection of prescribing errors by hospital pharmacy staff |
| Q53888126 | Cryptococcal Meningitis. |
| Q38111887 | Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries |
| Q41486149 | Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases |
| Q41864040 | Crystal structure and hydrogen-bonding patterns in 5-fluoro-cytosinium picrate |
| Q43056543 | Crystal structure of 4-amino-5-fluoro-2-oxo-2,3-di-hydro-pyrimidin-1-ium 3-hy-droxy-pyridine-2-carboxyl-ate |
| Q36233506 | Current use of anti-infectives in dermatology |
| Q43088855 | Cytosine deaminase as a negative selectable marker for the microalgal chloroplast: a strategy for the isolation of nuclear mutations that affect chloroplast gene expression. |
| Q58586221 | Decavanadate Salts of Cytosine and Metformin: A Combined Experimental-Theoretical Study of Potential Metallodrugs Against Diabetes and Cancer |
| Q37157893 | Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents |
| Q34057996 | Deletion of the uracil permease gene confers cross-resistance to 5-fluorouracil and azoles in Candida lusitaniae and highlights antagonistic interaction between fluorinated nucleotides and fluconazole |
| Q36738130 | Dematiaceous fungi |
| Q37217325 | Development and application of neural stem cells for treating various human neurological diseases in animal models |
| Q28362118 | Development of Saccharomyces cerevisiae as a model pathogen. A system for the genetic identification of gene products required for survival in the mammalian host environment |
| Q38658275 | Development of antifungal therapies using nanomaterials |
| Q37845680 | Development of proteomics-based fungicides: new strategies for environmentally friendly control of fungal plant diseases |
| Q33743558 | Distinct and redundant roles of protein tyrosine phosphatases Ptp1 and Ptp2 in governing the differentiation and pathogenicity of Cryptococcus neoformans |
| Q35336154 | Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections |
| Q35214480 | Effect of a denture base acrylic resin containing silver nanoparticles on Candida albicans adhesion and biofilm formation. |
| Q34077069 | Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. |
| Q34301547 | Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. |
| Q92034332 | Efficient exogenous DNA-free reprogramming with suicide gene vectors |
| Q37989984 | Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy |
| Q29616758 | Epidemiology of invasive candidiasis: a persistent public health problem |
| Q90835756 | Eradication of Candida albicans persister cell biofilm by the membranotropic peptide gH625 |
| Q35186963 | Essential Oils, Silver Nanoparticles and Propolis as Alternative Agents Against Fluconazole Resistant Candida albicans, Candida glabrata and Candida krusei Clinical Isolates |
| Q37925096 | European expert opinion on the management of invasive candidiasis in adults |
| Q38469574 | Evaluation of Hepatotoxicity with Treatment Doses of Flucytosine and Amphotericin B for Invasive Fungal Infections |
| Q28729144 | Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer |
| Q43828249 | Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology |
| Q57827086 | Experimental and Computational Hydrate Screening: Cytosine, 5-Flucytosine and Their Solid Solution |
| Q26800255 | Exploiting Fungal Virulence-Regulating Transcription Factors As Novel Antifungal Drug Targets |
| Q40957845 | False-negative cerebrospinal fluid fungal culture results following oral antineoplastic therapy with a 5-fluorouracil derivative |
| Q28534687 | Fitness trade-offs restrict the evolution of resistance to amphotericin B |
| Q33424943 | Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy |
| Q40170223 | Flucytosine and Amphotericin B Coadministration Induces Dose-Related Renal Injury. |
| Q27012487 | Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal |
| Q37263307 | Flucytosine antagonism of azole activity versus Candida glabrata: role of transcription factor Pdr1 and multidrug transporter Cdr1. |
| Q44154004 | Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration |
| Q34883912 | Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter |
| Q39220008 | Flucytosine-induced colitis |
| Q57176570 | Flux, Impact, and Fate of Halogenated Xenobiotic Compounds in the Gut |
| Q35868375 | Functional assignment of YvgO, a novel set of purified and chemically characterized proteinaceous antifungal variants produced by Bacillus thuringiensis SF361 |
| Q36208812 | Fungal Glycolipid Hydrolase Inhibitors and Their Effect on Cryptococcus neoformans. |
| Q38786061 | Future therapies targeted towards eliminating Candida biofilms and associated infections. |
| Q30397156 | GMP Synthase Is Required for Virulence Factor Production and Infection by Cryptococcus neoformans. |
| Q39111100 | Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases |
| Q40131868 | Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma |
| Q35070838 | Human pharmacogenomic variations and their implications for antifungal efficacy |
| Q41838182 | Hydrogen-bonding patterns in 5-fluoro-cytosine-melamine co-crystal (4/1). |
| Q91933801 | Identification of a Phenylthiazole Small Molecule with Dual Antifungal and Antibiofilm Activity Against Candida albicans and Candida auris |
| Q38790788 | Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes |
| Q38955988 | Improved cytotoxic effects of Salmonella-producing cytosine deaminase in tumour cells. |
| Q36000485 | Improved negative selection protocol for Plasmodium berghei in the rodent malarial model. |
| Q36993501 | In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus. |
| Q34142406 | In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. |
| Q35551018 | In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals. |
| Q36492208 | In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus |
| Q36314153 | In vitro inhibitory effects of farnesol and interactions between farnesol and antifungals against biofilms of Candida albicans resistant strains |
| Q39652783 | In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. |
| Q40882541 | In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models |
| Q46696611 | In vitro postantifungal effect, adhesion traits and haemolysin production of Candida dubliniensis isolates following exposure to 5-fluorocytosine |
| Q33938023 | Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae. |
| Q30907922 | Inclusion complex of a new propiconazole derivative with β-cyclodextrin: NMR, ESI-MS and preliminary pharmacological studies. |
| Q35076919 | Inhibition of nucleic acid biosynthesis makes little difference to formation of amphotericin B-tolerant persisters in Candida albicans biofilm |
| Q37534681 | Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B. |
| Q39296297 | Insertion of a nuclear factor kappa B DNA nuclear-targeting sequence potentiates suicide gene therapy efficacy in lung cancer cell lines |
| Q37719545 | Interactions between antifungal and antiretroviral agents |
| Q36822025 | Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome |
| Q38180287 | Invasive fungal infections in the ICU: how to approach, how to treat. |
| Q64093362 | Ionic Liquids Chemical Stress Triggers Sphingoid Base Accumulation in |
| Q64066303 | Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy |
| Q30425422 | Large-scale reverse docking profiles and their applications. |
| Q64120011 | Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Pathogens |
| Q40809158 | Liposomal flucytosine capped with gold nanoparticle formulations for improved ocular delivery |
| Q35005086 | Loss of heterozygosity of FCY2 leading to the development of flucytosine resistance in Candida tropicalis |
| Q34280580 | Management of Candida species infections in critically ill patients |
| Q37762556 | Mechanisms of antifungal drug resistance in Candida dubliniensis |
| Q24633163 | Melanized Fungi in Human Disease |
| Q37521304 | Membrane Proteomics Analysis of the Candida glabrata Response to 5-Flucytosine: Unveiling the Role and Regulation of the Drug Efflux Transporters CgFlr1 and CgFlr2. |
| Q40497992 | Mode of Action of a Designed Antimicrobial Peptide: High Potency against Cryptococcus neoformans |
| Q42956900 | Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. |
| Q40289630 | Molecular mechanisms of primary resistance to flucytosine in Candida albicans |
| Q84551050 | Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata |
| Q91707611 | Multiplex Genetic Engineering Exploiting Pyrimidine Salvage Pathway-Based Endogenous Counterselectable Markers |
| Q42376066 | Mutational Analysis of Flucytosine Resistance in Candida glabrata |
| Q35728840 | Mycoplasmas and cancer: focus on nucleoside metabolism |
| Q57900034 | Mycoses and Antifungals: reviewing the basis of a current problem that still is a biotechnological target for marine products |
| Q28552626 | NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning |
| Q48360437 | Neural stem cell-based dual suicide gene delivery for metastatic brain tumors |
| Q28547198 | New Mechanisms of Flucytosine Resistance in C. glabrata Unveiled by a Chemogenomics Analysis in S. cerevisiae |
| Q46576615 | New agents for the treatment of systemic fungal infections--current status. |
| Q34481647 | New developments in chemotherapy for non-invasive fungal infections |
| Q38797864 | New facets of antifungal therapy |
| Q94464436 | Nine Things Genomics Can Tell Us About Candida auris |
| Q42183289 | Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae. |
| Q28830321 | Novel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of Cryptococcus neoformans in macrophages |
| Q37829442 | Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002-2010). |
| Q37079085 | Oesophageal candidiasis in elderly patients: risk factors, prevention and management |
| Q37726198 | Opportunistic invasive fungal infections: diagnosis & clinical management |
| Q37621562 | Pancreatic cancer: gene therapy approaches and gene delivery systems |
| Q74059600 | Pharmacoepidemiology and drug safety |
| Q38193337 | Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. |
| Q38681635 | Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients |
| Q57533011 | Pharmacology of Systemic Antifungal Agents |
| Q53166301 | Phosphorylation of thymidylate synthase affects slow-binding inhibition by 5-fluoro-dUMP and N(4)-hydroxy-dCMP. |
| Q52926328 | Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. |
| Q60175850 | Pre-Existing Liver Disease and Toxicity of Antifungals |
| Q40844582 | Profiling of the effects of antifungal agents on yeast cells based on morphometric analysis |
| Q28478335 | Quantitative and qualitative analyses of the cell death process in Candida albicans treated by antifungal agents |
| Q28484112 | Quantitative and qualitative analysis of the antifungal activity of allicin alone and in combination with antifungal drugs |
| Q60922204 | Rad53- and Chk1-Dependent DNA Damage Response Pathways Cooperatively Promote Fungal Pathogenesis and Modulate Antifungal Drug Susceptibility |
| Q34580201 | Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector |
| Q34335236 | Rationale for combination antifungal therapy |
| Q36634450 | Recent insights into the mechanisms of antifungal resistance |
| Q60920672 | Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant |
| Q40187481 | Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors. |
| Q34338060 | Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity |
| Q47107191 | Requirement for Ergosterol in Berberine Tolerance Underlies Synergism of Fluconazole and Berberine against Fluconazole-Resistant Candida albicans Isolates |
| Q28731332 | Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes |
| Q36602123 | Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types |
| Q59286547 | Résistance des Candida aux antifongiques : détection et mécanismes |
| Q34463785 | Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma |
| Q90578032 | Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update |
| Q37449030 | Specifically targeted gene therapy for small-cell lung cancer. |
| Q40761531 | Structural, electronic and energetic consequences of epigenetic cytosine modifications. |
| Q91790885 | Synthesis of 4-amino-5-fluoropyrimidines and 5-amino-4-fluoropyrazoles from a β-fluoroenolate salt |
| Q35338420 | Systematic functional profiling of transcription factor networks in Cryptococcus neoformans |
| Q36277911 | Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay |
| Q37562147 | The Mechanistic Targets of Antifungal Agents: An Overview |
| Q39018200 | The current treatment landscape: candidiasis |
| Q52334121 | The mechanistic basis of pH-dependent 5-flucytosine resistance in Aspergillus fumigatus. |
| Q34854161 | The synthetic amphipathic peptidomimetic LTX109 is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent manner |
| Q33725213 | The transposon impala is activated by low temperatures: use of a controlled transposition system to identify genes critical for viability of Aspergillus fumigatus |
| Q55457164 | Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. |
| Q38738090 | Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations |
| Q36233517 | Therapy of infections caused by dematiaceous fungi |
| Q37544911 | Tissue penetration of antifungal agents. |
| Q40760304 | Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models |
| Q50170029 | Tolerability profile of the current antifungal armoury. |
| Q40651485 | Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy |
| Q57275580 | Treatment for HIV-associated cryptococcal meningitis |
| Q38609687 | Treatment of Fungal Urinary Tract Infection |
| Q37255172 | Treatment of invasive candidiasis in immunocompromised pediatric patients |
| Q35664186 | Treatment principles for Candida and Cryptococcus |
| Q49722503 | Two inhibitors of yeast plasma membrane ATPase 1 (ScPma1p): toward the development of novel antifungal therapies |
| Q37071133 | Use of terbinafine in rare and refractory mycoses |
| Q35598950 | Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method |
| Q89559203 | Virulence and biofilms as promising targets in developing antipathogenic drugs against candidiasis |
| Q38696236 | Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches. |
| Q44420165 | What is the role of therapeutic drug monitoring in antifungal therapy? |
| Q28481716 | Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis |
| Q84149141 | [Pharmacokinetics and pharmacodynamics of antifungal drugs in children] |
| Q64059158 | study of 4-phosphorylated derivatives of 1,3-oxazole as inhibitors of fructose-1,6-bisphosphate aldolase II |
Search more.